grant
Understanding Tumor Suppressive Functions of Protein Phosphatase 2A
Organization UNIVERSITY OF NEBRASKA MEDICAL CENTERLocation OMAHA, UNITED STATESPosted 1 May 2026Deadline 30 Apr 2031
NIHUS FederalResearch GrantFY20264E-BP1AddressAntioncogene Protein p53ApoptoticBeta Cadherin-Associated ProteinBeta-1 CateninBindingBone-Derived Transforming Growth FactorCUL-2Cancer CauseCancer EtiologyCancer GenesCancer-Promoting GeneCancersCap Binding ProteinsCell Communication and SignalingCell CycleCell Division CycleCell SignalingCellular Tumor Antigen P53Cessation of lifeClinicalClinical ManagementColorectal CancerColorectal NeoplasmsColorectal TumorsDNA mutationDPC4DataDeathDeleted in Pancreatic CarcinomaDependenceDephosphorylationDevelopmentDisablingDiseaseDisorderDown-RegulationDrosophila Homolog of Mothers Against Decapentaplegic 4DrugsEIF-4FEIF4EBP1EIF4EBP1 geneEIF4FEIF4F Translation Initiation ComplexEarly-Stage Clinical TrialsEukaryotic Initiation Factor-4FFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2FailureGatekeepingGenetic ChangeGenetic defectGenetic mutationGluesGrowth AgentsGrowth FactorGrowth SubstancesHealthHoloenzymesHyperactivityInduction of ApoptosisIntracellular Communication and SignalingInvestmentsKnock-outKnockoutLarge Bowel TumorLarge Intestine NeoplasmLarge Intestine TumorLeadLettersMADH4MADH4 geneMalignant CellMalignant NeoplasmsMalignant TumorMechanistic Target of RapamycinMediatingMedicationMessenger RNAMilk Growth FactorMolecularMolecular InteractionMolecular Tumor SuppressionMutationOncogenesOncogenicOncoprotein p53P53PI-3K/AKTPI3K/AKTPRO2286Pathway interactionsPatientsPb elementPeptide Initiation Factor EIF-4FPharmaceutical PreparationsPhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePhosphatasesPhosphohydrolasesPhosphomonoesterasesPhosphoprotein P53Phosphoprotein PhosphatasePhosphoprotein Phosphatase-2CPhosphoprotein PhosphohydrolasePhosphoprotein pp53Phosphoric Monoester HydrolasesPhosphorylationPhosphorylation SitePlatelet Transforming Growth FactorPre-Clinical ModelPreclinical ModelsProliferatingProtein BiosynthesisProtein DephosphorylationProtein Initiation Factor EIF-4FProtein Phosphatase CProtein Phosphatase GeneProtein Phosphatase-1Protein Phosphatase-2AProtein PhosphorylationProtein Synthesis InhibitionProtein TP53Protein phosphataseProteinsProteins Growth FactorsProteomeRAFT1RNA Cap-Binding ProteinsRNA HelicaseRas/RafResistanceRibosomal Peptide BiosynthesisRibosomal Protein BiosynthesisRibosomal Protein SynthesisRoleSMA- and MAD-Related Protein 4SMAD4SPHK1 enzymeSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSurvival RateTGF BTGF-betaTGF-βTGFbetaTGFβTP53TP53 geneTRP53TestingTherapeuticToxic effectToxicitiesTransforming GenesTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslation InitiationTranslational InhibitionTranslational RepressionTranslationsTumor Protein p53Tumor Protein p53 GeneTumor SuppressionTumor Suppressor ProteinsUpregulationWomananti-tumor effectantitumor effectbeta catbeta cateninbiological signal transductioncancer cellcancer typeclinical developmentclinical relevanceclinical translationclinically relevantclinically translatablecolorectal cancer progressioncolorectal cancer therapycolorectal cancer treatmentcolorectal neoplasiaconstitutive expressionconstitutive gene expressiondevelopmentaldrug/agenteffective therapyeffective treatmentfunctional restorationgatekeepergenome mutationheavy metal Pbheavy metal leadinhibitorlarge bowel neoplasmmRNAmRNA Cap Binding ProteinsmRNA TranslationmTORmTOR Inhibitormalignancymammalian target of rapamycinmenmetastatic colo-rectalmetastatic colo-rectal cancermetastatic colo-rectal carcinomametastatic colon cancermetastatic colorectalmetastatic colorectal cancermetastatic colorectal carcinomaneoplasm/cancernew approachesnovelnovel approachesnovel strategiesnovel strategyp53 Antigenp53 Genesp53 Tumor Suppressorpathwayphase I protocolprogramsprotein functionprotein p53protein synthesisrecruitresistance to therapyresistantresistant to therapyrestorationrestore functionrestore functionalityrestore lost functionscaffoldscaffoldingsmall moleculesocial rolesphingosine kinase-1statisticstargeted agenttargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttranslationtreatment resistancetumortumor suppressorβ-catenin
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Colorectal Cancer (CRC) is the third most common cancer in men and women. While the 5-year survival rate
for localized CRC is 91%, the survival rate is less than 14% for patients with disseminated disease. With few
exceptions, metastatic CRC is incurable, largely due to resistance to available therapies. As a result, CRC is the
second leading…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click